ARTICLE | Clinical News
GLPG1205: Completed Phase II enrollment
July 13, 2015 7:00 AM UTC
Galapagos completed enrollment of about 60 patients with moderate to severe UC in the double-blind, placebo-controlled, international Phase II ORIGIN trial evaluating 100 mg oral GLPG1205 once daily f...